Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

Harrow Inc Com

Harrow Health ( ($HROW) ) has provided an announcement. On March 24, 2026, Harrow, Inc. entered into a purchase agreement with BTIG, LLC and other ...

Harrow Health Expands Senior Notes Offering for Growth

Craig-Hallum analyst Chase Knickerbocker reiterated a Buy rating on Harrow Health today and set a price target of $59.00. Knickerbocker covers the ...

Craig-Hallum Keeps Their Buy Rating on Harrow Health (HROW)

An announcement from Harrow Health ( ($HROW) ) is now available. On March 24, 2026, Harrow, Inc. launched a private add-on offering of $50 million ...

Harrow Health Announces $50 Million Senior Notes Offering

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on X4 Pharmaceuticals (XFOR – Research Report), Boston ...

Market Cap	$1.30B	P/E Ratio	42.38
52W High	$54.85	52W Low	$20.85
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	10.8%	52W Position	48.4%
Overall Score	44	Value Score	35
Quality Score	52	Technical Score	45

EPS Current Est	$0.88	EPS Next Est	$2.65
EPS Growth Est	+201.1%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	HROW	$37.29	0.00%	266.99K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	HROW	$37.29	0%	266.99K
3
4
5
6

HROW

HROW

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Harrow Inc Com Data in Excel

Get Harrow Inc Com Data in Excel